Risk Management



2018 September Alert: CyPass Advice

September 16, 2018 Alert

Clinical Advice on CyPass Issued

Dear OMIC Policyholder,

We are contacting you with an update to our email of September 21, 2018. Please check https://www.omic.com/alcon-voluntary-withdrawal-of-cypass-glaucoma-device/ for future updates, as well as links to the materials discussed below.

Risk management recommendations
OMIC recommends that you take the following steps to promote patient safety and reduce your liability exposure:

  • Notify patients with CyPass of the market withdrawal in a letter sent via regular mail. Our sample letter to patients is available at https://www.omic.com/alcon-voluntary-withdrawal-of-cypass-glaucoma-device/.
  • Place a copy of the letter in the patient’s medical record, and send a copy to the referring ophthalmologist or optometrist.
  • When you do examine the patient, determine if there are any signs of unexpected endothelial cell loss or other problems.
  • Share your findings with the patient, and explain your plan for monitoring the eye.
  • Document the findings and discussion.

Clinical guidance and additional information are available from both Alcon and ASCRS.

OMIC policyholders may obtain confidential advice by contacting our Risk Management Hotline at 800-562-6642, option 4, or riskmanagement@omic.com.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

#5. Expertise unmatched.

OMIC's sole mission is to serve ophthalmology. The premier source of ophthalmic claims data and loss prevention materials, OMIC's member hotline is the most used ophthalmic consultative service of its kind and OMIC.com is the most visited web site in America for ophthalmic risk management advice and patient consent documents.

61864684